Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma

详细信息    查看全文

• 作者：Kevin Y Xu (1)
  Shenhong Wu (2) (3)
  
  1. Department of Medical Education ; Icahn School of Medicine at Mount Sinai ; New York ; NY ; USA
  2. Division of Hematology/Oncology ; Department of Medicine ; Stony Brook University School of Medicine ; Room ; HSC 15-053E ; Stony Brook ; NY ; USA
  3. Northport VA Medical Center ; Northport ; NY ; USA
  
• 关键词：Renal cell carcinoma ; Clear cell ; Non ; clear cell ; PD ; 1 ; Tyrosine kinase inhibitor
• 刊名：Biomarker Research
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：3
• 期：1
• 全文大小：320 KB
• 参考文献：1. Siegel, R, Naishadham, D, Jemal, A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: pp. 10-29 CrossRef
  2. Cowey, CL, Rathmell, WK (2009) VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 11: pp. 94-101 CrossRef
  3. Logan, JE, Rampersaud, EN, Sonn, GA, Chamie, K, Belldegrun, AS, Pantuck, AJ (2012) Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol 14: pp. 65-78
  4. Thompson Coon, J, Hoyle, M, Green, C, Liu, Z, Welch, K, Moxham, T (2010) Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 14: pp. 1-184 CrossRef
  5. Escudier, B, Pluzanska, A, Koralewski, P, Ravaud, A, Bracarda, S, Szczylik, C (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: pp. 2103-11 CrossRef
  6. Sternberg, CN, Davis, ID, Mardiak, J, Szczylik, C, Lee, E, Wagstaff, J (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: pp. 1061-8 CrossRef
  7. Escudier, B, Eisen, T, Stadler, WM, Szczylik, C, Oudard, S, Siebels, M (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: pp. 125-34 CrossRef
  8. Rini, BI, Escudier, B, Tomczak, P, Kaprin, A, Szczylik, C, Hutson, TE (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: pp. 1931-9 CrossRef
  9. Hudes, G, Carducci, M, Tomczak, P, Dutcher, J, Figlin, R, Kapoor, A (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: pp. 2271-81 CrossRef
  10. Kalra, S, Verma, J, Atkinson, BJ, Matin, SF, Wood, CG, Karam, JA (2014) Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. Book Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era (Editor ed.^eds.). 2014 Genitourinary Cancers Symposium, City
  11. Ribas, A, Hodi, FS, Kefford, R, Hamid, O, Daud, A, Wolchok, JD (2014) Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. Book Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (Editor ed.^eds.). ASCO Annual Meeting, City
  12. Sznol, M, Kluger, HM, Callahan, MK, Postow, MA, Gordon, RA, Segal, NH (2014) Survival, response duration, and activity by BRAF mutation status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma. Book Survival, response duration, and activity by BRAF mutation status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (Editor ed.^eds.). ASCO Annual Meeting, City
  13. Hammers, HJ, Plimack, ER, Infante, JR, Ernstoff, MS, Rini, BI, McDermott, D (2014) Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). Book Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (Editor ed.^eds.). American Society of Clinical Oncology (ASCO), City
  14. Gunturi, A, McDermott, DF (2014) Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol 15: pp. 137-46 CrossRef
  15. Motzer, RJ, Rini, BI, McDermott, DF, Redman, BG, Kuzel, T, Harrison, MR (2014) Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase trial. Book Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase trial (Editor ed.^eds.). ASCO Annual Meeting, City
  16. Choueiri, TK, Fishman, MN, Escudier, B, Kim, JJ, Kluger, HM, Stadler, WM (2014) Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. Book Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial (Editor ed.^eds.). ASCO Annual Meeting, City
  17. Motzer, RJ, Hutson, TE, Tomczak, P, Michaelson, MD, Bukowski, RM, Rixe, O (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: pp. 115-24 CrossRef
  18. Motzer, RJ, Escudier, B, Oudard, S, Hutson, TE, Porta, C, Bracarda, S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: pp. 449-56 CrossRef
  19. Tannir, NM, Jonasch, E, Altinmakas, E, Ng, CS, Qiao, W, Tamboli, P (2014) Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): a multicenter randomized phase 2 trial. Book Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial (Editor ed.^eds.). ASCO Annual Meeting, City
  20. Hudes, GR (2009) Targeting mTOR in renal cell carcinoma. Cancer 115: pp. 2313-20 CrossRef
  
• 刊物主题：Biomedicine general;
• 出版者：BioMed Central
• ISSN：2050-7771

文摘

The advent of new knowledge surrounding the molecular pathology of renal-cell carcinoma (RCC) has culminated in a number of emerging targeted therapies. In just the last year, several new studies have been able to translate our understanding of tumor biology into significantly improved outcomes in patients with advanced RCC. The objective of this review is to describe new developments in targeted treatments and immunotherapies for patients with both clear-cell and non-clear cell metastatic RCC following the 2014 American Society of Clinical Oncology (ASCO) annual conference. We will discuss new applications of anti-VGF agents and PD-1 inhibitors in order to shed light on emerging avenues of RCC treatment that show considerable promise.